Insulin-related metabolic changes during treatment with valproate in patients with epilepsy (Q43799181)

26 November 2017

Insulin-related metabolic changes during treatment with valproate in patients with epilepsy (English)

1 reference

26 November 2017

1 reference

Mikael Knip

3

0 references

author name string

Virpi Pylvänen

series ordinal

1

1 reference

PubMed ID

16600693

26 November 2017

Arto Pakarinen

series ordinal

2

1 reference

PubMed ID

16600693

26 November 2017

Jouko Isojärvi

series ordinal

4

1 reference

26 November 2017

5 April 2006

1 reference

26 November 2017

1 reference

26 November 2017

8

1 reference

26 November 2017

643-648

1 reference

26 November 2017

3

1 reference

Obesity and endocrine disorders in women taking valproate for epilepsy.

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Serum insulin and leptin levels in valproate-associated obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Characterization of insulin secretion in Valproate-treated patients with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Banting lecture 1988. Role of insulin resistance in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Altered ovarian function and cardiovascular risk factors in valproate-treated women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Anticardiolipin and antinuclear antibodies in epilepsy--a population-based cross-sectional study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Fasting serum insulin and lipid levels in men with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Valproate and mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Antiepileptic drugs reduce serum uric acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Plasma uric acid in patients receiving anticonvulsant monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Uric acid as a risk factor for cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Thyroid Function with Antiepileptic Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Effects of Anticonvulsant Drugs on Thyroid Hormones in Epileptic Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Thyroid hormone concentrations in epileptic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Medical Consequences of Obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

Weight gain during treatment with valproate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.02.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YEBEH.2006.02.008

1 reference

26 November 2017

1 reference

PubMed ID

16600693